Skip to main content

Man E. Charurat, PhD, MHS

Academic Title:

Professor

Primary Appointment:

Medicine

Secondary Appointment(s):

Epidemiology & Public Health

Administrative Title:

Division Director Of Epidemiology & Prevention At The Institute Of Human Virology

Additional Title:

Director, Division of Epidemiology and Prevention, Institute of Human Virology

Location:

Institute of Human Virology, 725 W. Lombard Street, Room 449N

Phone (Primary):

410-706-1948

Fax:

410-706-1944

Education and Training

  • University of Washington, BS, Biochemistry and English, 1996
  • Johns Hopkins University, MHS, Infectious Disease Epidemiology, 1999
  • Johns Hopkins University, PhD, International Health, 2002

Biosketch

As the Director of IHV Division of Epidemiology and Prevention and trained infectious disease epidemiologists Dr. Charurat has over 15 years of research experience in among vulnerable and key populations, HIV treatment and prevention service delivery, and HIV surveillance of acute HIV infection in high-risk populations. In the mid-1990’s, Dr. Charurat was an active investigator in the NIH-funded Women and Infants Transmission Study (WITS) when mother-to-child HIV transmission was fairly high in the U.S., and in the early 2000’s he pioneered the mobile recruitment platform that successfully provided PEPFAR services to key populations such as female sex workers, men who have sex with men, and higher-risk pregnant women (CDC 200-2003-01716.)  Dr. Charurat published a first molecular characterization of circulating HIV-1 infections in Nigeria and is working with the CDC and the GON to improve incidence rate determination and surveillance across different populations in Nigeria. He is current PI on three R01s: R01DE025174 characterizes microbiome among HIV-Exposed but uninfected infants in Nigeria; R01AI120913 targets marginalized MSM and determine intervention for treatment as prevention (TasP) and pre-exposure prophylaxis ARV (PrEP);  and 1R01HD089866, an HIV adolescent transition to adult care study.  Additionally, he just completed R01MH099001 studying barriers to engaging MSM in services in Nigeria.  Furthermore, Dr. Charurat is PI of two the CDC-funded quality projects, the Nigerian Alliance for Health Systems Strengthening (1U2GH000656) grant focused on clinical quality improvement and the Strengthening HIV Field Epidemiology, Infectious Diseases Surveillance, and Lab Diagnostics project (1NU2GGH001976).  In summary, Dr. Charurat has expertise in leading epidemiology grants targeted to vulnerable populations, particularly MSM. 

Research/Clinical Keywords

HIV Virus, HIV prevention, Mother-to-infant transmission of HIV, Antiretroviral Therapy Program, Key Population, Surveillance, Microbiome, HIV Adolescent, Health Systems Strengthening, PMTCT

Highlighted Publications

Dr. Charurat has published over 70 peer-reviewed journal articles. A few of his most highly are listed below:

  1. Cooper ER, Charurat M, Burns D, Blattner WA, and Hoff R.  Trends in antiretroviral therapy and mother-to-infant transmission of HIV.  JAIDS.  2000 May 1;24:45-47.
  2. Cooper ER, Charurat M, Mofenson L, Hanson C, Pitt J, Diaz C, Hayani K, Handelsman E, Smeriglio V, Blattner WA.  Combination antiretroviral strategies for the treatment of pregnant HIV-1infected women and prevention of perinatal HIV-1 transmission.  JAIDS. 2002 Apr 15;29:484-494.
  3. Charurat M, Blattner W, Hershow R, Buck A, Zorilla C, Watts H, Paul M, Landesman S, Hay C, Smeriglio V, Adeniyi-Jones S, Tuomala R.  Changing trends in clinical AIDS presentations and survival among human immunodeficiency virus infected women.  J Womens Health. 2004;13(6):719-30.
  4. Blattner WA, Oursler KA, Cleghorn FR, Charurat M, Sill A, Bartholomew C, et al.  Rapid viral clearance following acute HIV-1 infection: Correlates of AIDS risk.  J Infect Dis.  2004 May 15;189(10):1793-801.
  5. Devico A, Fouts T, Lewis GK, Gallo RC, Godfrey K, Charurat M, Harris I, Galmin L, Pal R.  Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci USA. 2007 Oct 30;104(44):17477-82.
  6. Maru S, Datong P, Selleng D, Mang E, Inyang B, Ajene A, Guyit R, Charurat M, Abimiku A. Social determinants of mixed feeding behavior among HIV-infected mothers in Jos, Nigeria. AIDS Care. 2009 Sep;21(9):1114-23.
  7. Charurat M, Oyegunle M, Benjamin R, Habib A, Eze E, Ele P, Ibanga I, Ajayi S, Eng M, Mondal P, Gebi U, Iwu E, Etiebet MA, Abimiku A, Dakum P, Farley J, Blattner W. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS One. 2010 May 11;5(5):e10584
  8. Ahmed S, Delaney K, Villalba-Diebold P, Aliyu G, Constantine N, Ememabelem M, Vertefeuille J, Blattner W, Nasidi A, Charurat M.  HIV counseling and testing and access-to-care needs of populations most-at-risk for HIV in Nigeria.  AIDS Care.  2013;25(1):85-94.  Epub 2012 Jul 10.
  9. Charurat M, Nasidi A, Delaney K, Saidu A, Croxton T, Eyzaguirre L, Mondal P, Aliyu G, Constantine N, Abimiku A, Carr JK, Vertefeuille J, Blattner WA.  Characterization of acute HIV-1 infection in high-risk Nigerian populations.  J Infect Dis.2012 Apr 15;205(8):1239-47.
  10. Omoni A, Christian P, Sadoh W, Okechukwu A, Olateju E, Omoigberale A, Blattner W, Charurat M.  Immunologic outcomes of antiretroviral therapy among HIV-infected Nigerian children and its association with early infant feeding and nutritional status at treatment initiation.  Ped Infect Dis J. 2013 Jul;23(7):e291-7.
  11. Charurat M, Emmanuel B, Akolo CA, Baral S, Ake J, Kennedy S, Emmanuel B, Orazulike I, Boulay M, Keshinro B, Blattner W.  Uptake of Treatment as Prevention and continuum of care among Men who have sex with men in Nigeria.  J Acquir Immune Defic Syndr.  2015 Mar 1;68 Suppl 2:S114-23.
  12. Baral S, Schwartz S, Orazulike I, Ketende S, Ugoh K, Peel S, Ake J, Blattner W, Charurat M.  Evaluating Respondent Driven Sampling for Recruiting MSM into HIV Prevention Study.   J Acquir Immune Defic Syndr.  2015 Mar 1; 68 Suppl 2:S107-13.
  13. Coker M, Etibet M, Chang H, Gambo A, Jumare J, Babashani M, Dakum P, Charurat M, Blattner W, Eng M, Ndembi N.  Socio-demographic and adherence factors associated with viral load suppression in HIV-infected adults initiating therapy in northern Nigeria: A randomized controlled trial of a peer support intervention.  Curr HIV Res.  Feb 2015;13(4):279-85.
  14. Omoni A, Christian P, Sadoh W, Okechukwu A, Olateju E, Omoigherale A, Blattner W, Charurat M.  Early infant feeding, growth and nutritional status of HIV-infected Nigeria preschool children receiving antirretroviral treatment.  J Nutr. 2015.  Accepted, July 14, 2015.  Letter of provisional acceptance enclosed.

Additional Publication Citations

Research Interests

Dr. Charurat’s research career began with studies of mother-to-child transmission of HIV, publishing on the ability of highly effective antiretroviral treatment of the mother to eliminate pediatric transmission and later documented the adverse consequences of “mixed” feeding of African infant.  Recently, through NIH R-01 funding, he began investigating HIV exposed uninfected infants and the role of the gut microbiome in developmental delays.  His studies involving most at risk populations are at the cutting edge of current global strategies.  His work in this arena documented the dynamics of acute HIV infection and laid the foundation for subsequent studies that mapped transmission hotspots which in turn led to successful NIH R-01 grant funding (TRUST Project) that employ sophisticated recruitment strategies to engage Men having Sex with Men in treatment and prevention services and documenting the impact of treatment as prevention.  Most recently, expanding upon the TRUST study, a new NIH RO1 grant (Building TRUST) integrates phylodynamic modeling to pattern incidence and prevalence over time.

Grants and Contracts

1R01DE025174-01, PI, 09/23/2014-07/31/2019, Microbiome and Health Outcomes among HIV-exposed Uninfected Infants  (MARGIN) - This study is investigating the acquisition of a distorted gastrointestinal (GI) microbiome resulting from exposure to maternal HIV infection in HIV-exposed but infected infants in Nigeria is associated with post- natal growth as measured by increased nutritional deficiencies, increased GI permeability, and adverse clinical outcomes.

 

1R01AI120913, NIH, PI, 07/01/2015-06/30/2020, Building TRUST - The WHO calls on the need to re-energize and strengthen HIV programs so that all high-risk “key populations” benefit from the on-going advances in HIV antiretroviral-based prevention methods.  Building TRUST studies a group of men who have sex with men in Nigeria to understand the barriers to effective treatment and prevention uptake in order to better prevent new infections and save lives of those infected.

 

1R01HD089866, NIH, MPI, 07/01/2016-06/30/2021, Adolescent to Adult Patient-centered HIV Transition (ADAPT) - The ADAPT study is a randomized trial of innovative interventions targeting gaps in care that are major drivers of loss in the ART continuum of care cascade among adolescents and increasing missed opportunities to engage adolescents into care.  The specific aims of ADAPT are: (a) to inform strategies for transition services in resource-limited settings; (b) to examine the developmental, clinical, and other factors that predict a successful transition; and (c) to gain fundamental insight on implementation barriers among African adolescents through the application of the ego-network defined social support that will inform targets for structured intervention.

 

1D43TW010051, NIH, MPI, 05/1/2016-4/30/2021, Epidemiology Training for Public Health Impact in Nigeria, Epi-Nigeria - This project provides HIV research training to develop the capacity of the Institute of Human Virology Nigeria (IHV-Nigeria) to position it as a research leader in achieving global health goals for preventing a resurgence of the epidemic by increasing efficiency of treatment and prevention services.

 

1NU2GGH001976, CDC, PI, 09/30/2016-09/29/2021, Strengthening HIV Field Epidemiology, Infectious Diseases Surveillance, and Lab Diagnostics Program (SHIELD) - The SHIELD project supports the PEPFAR Nigeria program to improve the quality of HIV service delivery through instituted M&E processes.  SHIELD builds on the existing capacity of the University of Maryland Baltimore (UMB) to collaborate with all 11 implementing partners who are supporting service deliveries through the CDC, USAID, and DOD funding programs. In Nigeria, UMB led by the School of Medicine, is a leading public health partner with the Government of Nigeria, several donors and local institutions.

 

1U2GH000656, CDC, PI, 09/30/2012-09/29/2017, Nigerian Alliance for Health Systems Strengthening - CDC-funded health system strengthening to achieve sustainable change in the Nigerian Health System

 

1U2GH000925, CDC, Co-Investigator, 09/30/2012-09/29/2017, HIV/AIDS Prevention, Care & Treatment in the Federal Republic of Nigeria (PI: Dakum) - This is a continuation of the UMB PEPFAR awarded to an indigenous partner in Nigeria.

Professional Activity

05/2004 – 06/2010 - Assistant Professor (Primary), Institute of Human Virology, Dept. of Medicine

03/2006 – 07/2010 - Assistant Professor (Secondary), University of Maryland School of Medicine, Department of Epidemiology and Preventive Medicine

04/2005 – present - Senior Technical Advisor, Institute of Human Virology, Nigeria

07/2010 – present - Associate Professor (Primary), Institute of Human Virology, Dept. of Medicine

08/2010 – present - Associate Professor (Secondary), University of Maryland School of Medicine, Department of Epidemiology and Public Health

07/2015 – present - Director, IHV Division of Epidemiology and Prevention

Links of Interest

Institute of Human Virology: http://www.ihv.org/

Department of Medicine: http://www.medschool.umaryland.edu/medicine/

Graduate Program in Epidemiology & Public Health: https://medschool.umaryland.edu/epidemiology/